Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Neoplasms, Second Primary"" wg kryterium: Temat


Tytuł:
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.
Autorzy:
Nofal S; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Niu J; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Resong P; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jin J; Information Services, Enterprise Development and Integration, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Merriman KW; Department of Tumor Registry, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Le X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katki H; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
Heymach J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Antonoff MB; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ostrin E; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wu J; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zhang J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Toumazis I; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5), pp. e7069.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/diagnosis
Lung Neoplasms*/epidemiology
Neoplasms, Second Primary*/diagnosis
Neoplasms, Second Primary*/epidemiology
Esophageal Neoplasms*
Humans ; Early Detection of Cancer ; Retrospective Studies ; Risk Factors ; Lung
Czasopismo naukowe
Tytuł:
Uncovering causal clues in the development of second primary cancers.
Autorzy:
Yi H; Department of Gynecological Oncology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, National Key Clinical Specialty Construction Program of Gynecology, Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fuzhou 350001, China; Center for Primary Health Care Research, Lund University, Malmö, Sweden. Electronic address: .
Ji J; Center for Primary Health Care Research, Lund University, Malmö, Sweden.
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2024 Mar; Vol. 25 (3), pp. e97.
Typ publikacji:
Letter
MeSH Terms:
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Humans
Opinia redakcyjna
Tytuł:
Uncovering causal clues in the development of second primary cancers - Authors' reply.
Autorzy:
Kjaer TK; Cancer Survivorship, Danish Cancer Institute, DK-2100 Copenhagen, Denmark. Electronic address: .
Johansen C; Center for Cancer Late Effects Research CASTLE, Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Dalton SO; Cancer Survivorship, Danish Cancer Institute, DK-2100 Copenhagen, Denmark; Danish Research Center for Equality in Cancer, Department of Clinical Oncology and Palliative care, Zealand University Hospital, Næstved, Denmark; Institute of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2024 Mar; Vol. 25 (3), pp. e98.
Typ publikacji:
Letter
MeSH Terms:
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/genetics
Humans
Opinia redakcyjna
Tytuł:
Second Malignancy Probabilities in Patients With Breast Cancer Treated With Conventional Versus Hypofractionated External Beam Radiation Therapy in the Adjuvant Setting.
Autorzy:
Patel TA; University of Pennsylvania, Philadelphia, PA, USA.
Jain B; Stanford School of Medicine, Stanford, CA, USA.
Cho HL; Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Corti C; Breast Oncology Program, Dana-Farber Cancer Centre, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
Vapiwala N; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Chino F; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Leeman JE; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: JonathanE_.
Dee EC; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło:
Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2024 Mar; Vol. 36 (3), pp. 183-192. Date of Electronic Publication: 2023 Dec 09.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/surgery
Breast Neoplasms*/pathology
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Humans ; Female ; Child, Preschool ; Mastectomy ; Retrospective Studies ; Risk ; Radiotherapy, Adjuvant/adverse effects
Czasopismo naukowe
Tytuł:
Impact of prior cancer history on survival in brain malignancy: A propensity score-adjusted, population-based study.
Autorzy:
Ebad Ur Rehman M; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Faraz F; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Cheema HA; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Ashruf OS; Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Raheel H; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Naqvi SZA; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Jabeen N; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Abid A; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Mumtaz Malik H; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Iftikhar A; Department of Medicine, The University of Arizona, Tucson, Arizona, USA.
Ibrahim A; Rawalpindi Medical University, Rawalpindi, Pakistan.
Swed S; Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Pokaż więcej
Źródło:
Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2024 Feb; Vol. 7 (2), pp. e1984.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*
Brain Neoplasms*/epidemiology
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/pathology
Humans ; Retrospective Studies ; Propensity Score ; SEER Program ; Kaplan-Meier Estimate
Czasopismo naukowe
Tytuł:
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Autorzy:
Geurts YM; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam.
Neppelenbroek SIM; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam.
Aleman BMP; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam.
Janus CPM; Department of Radiotherapy, Erasmus Medical Centre, Rotterdam.
Krol ADG; Department of Radiation Oncology, Leiden University Medical Centre, Leiden.
van Spronsen DJ; Department of Hematology, Radboud University Medical Centre, Nijmegen.
Plattel WJ; Department of Hematology, University Medical Centre Groningen, Groningen.
Roesink JM; Department of Radiotherapy, University Medical Centre Utrecht, Utrecht.
Verschueren KMS; Department of Radiation Oncology, Institute Verbeeten, Tilburg.
Zijlstra JM; Department of Hematology, Amsterdam UMC location Vrije Universiteit, Cancer Centre Amsterdam, Amsterdam.
Koene HR; Department of Internal Medicine, St. Antonius Hospital, Nieuwegein.
Nijziel MR; Catharina Cancer Institute, Department of Hemato-Oncology, Catharina Hospital, Eindhoven.
Schimmel EC; Radiotherapiegroep, Arnhem.
de Jongh E; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
Ong F; Department of Radiotherapy, Medisch Spectrum Twente, Enschede.
Te Boome LCJ; Department of Hematology, Haaglanden Medical Centre, The Hague.
van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden.
Böhmer LH; Department of Hematology, Haga Teaching Hospital, The Hague.
Ta BDP; Department of Radiation Oncology (MAASTRO), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht.
Visser HPJ; Department of Hematology, Noordwest Ziekenhuisgroep Alkmaar, Alkmaar.
Posthuma EFM; Department of Internal Medicine, Reinier de Graaf Hospital, Delft.
Bilgin YM; Department of Internal Medicine, ADRZ, Goes.
Muller K; Radiotherapiegroep, Deventer.
van Kampen D; Zuidwest Radiotherapeutisch Instituut, Vlissingen.
So-Osman C; Department of Hematology, Erasmus Medical Centre, Rotterdam; Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam.
Vermaat JSP; Department of Hematology, Leiden University Medical Centre, Leiden.
de Weijer RJ; Department of Hematology, University Medical Centre Utrecht, Utrecht.
Kersten MJ; Department of Hematology, Amsterdam UMC location University of Amsterdam, Cancer Centre Amsterdam and LYMMCARE, Amsterdam, The Netherlands.
van Leeuwen FE; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam.
Schaapveld M; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam. Electronic address: .
Pokaż więcej
Źródło:
ESMO open [ESMO Open] 2024 Feb; Vol. 9 (2), pp. 102248. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Lymphoma, Large B-Cell, Diffuse*/epidemiology
Humans ; Rituximab/adverse effects ; Survivors ; Cyclophosphamide ; Doxorubicin
Czasopismo naukowe
Tytuł:
Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
Autorzy:
Bárcena PGQ; Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Aprikian AG; Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada.; McGill University Health Centre, Montreal, Quebec, Canada.
Dragomir A; Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Faculty of pharmacy, University of Montreal, Montreal, Quebec, Canada.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6922. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/epidemiology
Prostatic Neoplasms*/therapy
Urinary Bladder Neoplasms*
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Colorectal Neoplasms*/epidemiology
Colorectal Neoplasms*/therapy
Male ; Humans ; Urinary Bladder ; Androgen Antagonists/adverse effects ; Cohort Studies
Czasopismo naukowe
Tytuł:
Nodular type but not vitamin D levels increases the risk of second primary cancers in melanoma patients: An observational study of 663 patients.
Autorzy:
Massa A; Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
Isasi-Fuster A; School of Medicine, Universidad Católica de Valencia San Vicente Mártir, València, Spain.
Requena C; Department of Dermatology, Fundación Instituto Valenciano de Oncología, València, Spain.
Manrique-Silva E; Department of Dermatology, Fundación Instituto Valenciano de Oncología, València, Spain.
Kumar R; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany; Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic.
Nagore E; School of Medicine, Universidad Católica de Valencia San Vicente Mártir, València, Spain; Department of Dermatology, Fundación Instituto Valenciano de Oncología, València, Spain. Electronic address: .
Pokaż więcej
Źródło:
Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2024 Feb; Vol. 115 (2), pp. 143-149. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Melanoma*/epidemiology
Melanoma*/etiology
Melanoma*/diagnosis
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Skin Neoplasms*/etiology
Skin Neoplasms*/complications
Vitamin D Deficiency*/complications
Vitamin D Deficiency*/epidemiology
Humans ; Middle Aged ; Vitamin D/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
Autorzy:
Lucijanic M; Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia. .; School of Medicine, University of Zagreb, Zagreb, Croatia. .
Tomasovic-Loncaric C; Pathology and Cytology Department, University Hospital Dubrava, Zagreb, Croatia.; Catholic University of Croatia, Zagreb, Croatia.
Stoos-Veic T; Pathology and Cytology Department, University Hospital Dubrava, Zagreb, Croatia.; Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
De Both T; Urology Department, University Hospital Dubrava, Zagreb, Croatia.
Jalsenjak B; Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Kusec R; Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia.
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Feb; Vol. 103 (2), pp. 671-672. Date of Electronic Publication: 2023 Nov 09.
Typ publikacji:
Letter
MeSH Terms:
Sarcoma, Myeloid*/complications
Sarcoma, Myeloid*/diagnosis
Sarcoma, Myeloid*/drug therapy
Leukemia, Myeloid, Acute*/complications
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Neoplasms, Second Primary*/diagnosis
Neoplasms, Second Primary*/drug therapy
Sulfonamides*
Humans ; Urinary Bladder ; Azacitidine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Opinia redakcyjna
Tytuł:
When the second comes first- rhabdomyosarcoma preceding heritable retinoblastoma- a case report.
Autorzy:
Tripathy D; LV Prasad Eye Institute, MTC Campus, Bhubaneswar, Odisha, India.; Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Moulin A; Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Bijon J; Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Gengler C; Unit of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Beck-Popovic M; Unit of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Munier FL; Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Stathopoulos C; Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland. .
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2024 Jan 30; Vol. 24 (1), pp. 47. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Neoplasms, Second Primary*/diagnosis
Neoplasms, Second Primary*/genetics
Retinal Neoplasms*/diagnosis
Retinal Neoplasms*/genetics
Retinal Neoplasms*/pathology
Retinoblastoma*/diagnosis
Retinoblastoma*/genetics
Retinoblastoma*/pathology
Rhabdomyosarcoma*/diagnosis
Rhabdomyosarcoma*/genetics
Child ; Humans ; Mutation ; Twins, Monozygotic
Czasopismo naukowe
Tytuł:
Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma.
Autorzy:
Wang L; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zheng Y; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Luo R; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Kang K; Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Niedermann G; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zhao A; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. .
Wu Y; Cancer Center, West China Hospital, Sichuan University, Chengdu, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Jan 27; Vol. 150 (2), pp. 41. Date of Electronic Publication: 2024 Jan 27.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms, Second Primary*/etiology
Neoplasms, Second Primary*/complications
Hodgkin Disease*/epidemiology
Hodgkin Disease*/complications
Lymphoma, Non-Hodgkin*/etiology
Lymphoma, Non-Hodgkin*/complications
Lymphoma*/complications
Child ; Humans ; Risk Assessment ; Incidence ; Risk Factors
Czasopismo naukowe
Tytuł:
HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Autorzy:
Yadav BS; Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India. .
Dahiya D; Department of General Surgery, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Kannan P; Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Goyal S; Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Laroiya I; Department of General Surgery, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Irrinki S; Department of General Surgery, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Singh NR; Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Sharma R; Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Pokaż więcej
Źródło:
Trials [Trials] 2024 Jan 02; Vol. 25 (1), pp. 21. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article
MeSH Terms:
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/surgery
Neoplasms, Second Primary*/complications
Neoplasms, Second Primary*/surgery
Radiation Injuries*/etiology
Humans ; Female ; Radiation Dose Hypofractionation ; Radiotherapy, Adjuvant/adverse effects ; Radiotherapy, Adjuvant/methods ; Mastectomy/adverse effects ; Quality of Life ; Treatment Outcome ; Neoplasm Recurrence, Local/pathology ; Adjuvants, Immunologic
Czasopismo naukowe
Tytuł:
Improved guideline compliance and textbook oncologic outcomes among patients undergoing multimodal treatment and minimally invasive surgery for locally advanced gastric cancer.
Autorzy:
Rawicz-Pruszyński K; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States; Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Tsilimigras DI; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States.
Endo Y; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States.
Munir MM; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States.
Katayama E; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States.
Benavides JG; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States.
Sędłąk K; Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Pelc Z; Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Pawlik TM; Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, United States. Electronic address: .
Pokaż więcej
Źródło:
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract [J Gastrointest Surg] 2024 Jan; Vol. 28 (1), pp. 10-17.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms, Second Primary*/surgery
Neoplasms, Second Primary*/therapy
Stomach Neoplasms*/surgery
Stomach Neoplasms*/therapy
Aged ; Female ; Humans ; Male ; Middle Aged ; Combined Modality Therapy ; Cross-Sectional Studies ; Gastrectomy ; Minimally Invasive Surgical Procedures ; Retrospective Studies ; Treatment Outcome ; United States ; Guideline Adherence/statistics & numerical data
Czasopismo naukowe
Tytuł:
Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018.
Autorzy:
van der Meer DJ; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam. Electronic address: .
van der Graaf WTA; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam.
van de Wal D; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam.
Karim-Kos HE; Princess Máxima Center for Pediatric Oncology, Utrecht; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht.
Husson O; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam; Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
ESMO open [ESMO Open] 2024 Jan; Vol. 9 (1), pp. 102203. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Cancer Survivors*
Breast Neoplasms*/epidemiology
Female ; Humans ; Male ; Adolescent ; Young Adult ; Netherlands/epidemiology ; Risk Factors
Czasopismo naukowe
Tytuł:
Busulfan and subsequent malignancy: An evidence-based risk assessment.
Autorzy:
Long-Boyle JR; University of California, San Francisco, California, USA.
Kohn DB; University of California, Los Angeles, California, USA.
Shah AJ; Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, California, USA.
Spencer SM; Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Sevilla J; Hematología y Hemoterapia, Fundación para la investigación Biomédica, Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain.
Booth C; Great Ormond Street Hospital, and Great Ormond Street Hospital NHS Foundation Trust, University College of London, Institute of Child Health, London, UK.
López Lorenzo JL; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Nicoletti E; Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Shah A; Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Reatz M; Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Matos J; Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Schwartz JD; Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Jan; Vol. 71 (1), pp. e30738. Date of Electronic Publication: 2023 Oct 19.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute*/pathology
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Graft vs Host Disease*/epidemiology
Adult ; Humans ; Child ; Busulfan/adverse effects ; Transplantation Conditioning/adverse effects ; Risk Assessment ; Vidarabine
Czasopismo naukowe
Tytuł:
Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.
Autorzy:
Avatefi M; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
HadavandSiri F; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nazari SSH; School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akbari ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2024 Jan; Vol. 7 (1), pp. e1927. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/diagnosis
Breast Neoplasms*/epidemiology
Breast Neoplasms*/therapy
Neoplasms, Second Primary*/diagnosis
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Female ; Humans ; Retrospective Studies ; Risk Factors ; Proportional Hazards Models
Czasopismo naukowe
Tytuł:
Gastrointestinal: Weight gain increases the risk of metachronous advanced colorectal neoplasm observed in post-polypectomy surveillance colonoscopy.
Autorzy:
Lee S; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Do YS; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Lee HJ; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim GU; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Park HW; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Chang HS; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Choe J; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Byeon JS; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Lee JY; Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2024 Jan; Vol. 39 (1), pp. 47-54. Date of Electronic Publication: 2023 Sep 25.
Typ publikacji:
Journal Article
MeSH Terms:
Colonic Polyps*/epidemiology
Colorectal Neoplasms*/diagnosis
Colorectal Neoplasms*/epidemiology
Colorectal Neoplasms*/etiology
Neoplasms, Second Primary*/diagnosis
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Male ; Humans ; Female ; Retrospective Studies ; Neoplasm Recurrence, Local/complications ; Colonoscopy/adverse effects ; Risk Factors ; Weight Gain
Czasopismo naukowe
Tytuł:
Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR.
Autorzy:
Scholz-Kreisel P; Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. .; Federal Offices for Radiation Protection, Neuherberg, Germany. .
Becker C; German Childhood Cancer Registry (GCCR) Division of Childhood Cancer Epidemiology at the Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Kaiser M; German Childhood Cancer Registry (GCCR) Division of Childhood Cancer Epidemiology at the Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Mahmoudpour SH; Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Voigt M; German Childhood Cancer Registry (GCCR) Division of Childhood Cancer Epidemiology at the Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Ressing M; German Childhood Cancer Registry (GCCR) Division of Childhood Cancer Epidemiology at the Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Blettner M; Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Calaminus G; Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
Baust K; Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
Scholtes C; Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
Zimmermann M; Department for Pediatric Hematology and Oncology, Children's Hospital, Medical School Hannover, Hannover, Germany.
Zeissig SR; Institute of Clinical Epidemiology and Biometry (ICE-B), University of Würzburg, Würzburg, Germany.; Regional Centre Würzburg, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Würzburg, Germany.
Schmidberger H; Department for Radiation Oncology and Radiotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Karle H; Department for Radiation Oncology and Radiotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Meyer-Oldenburg S; Department for Radiation Oncology and Radiotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Kaatsch P; German Childhood Cancer Registry (GCCR) Division of Childhood Cancer Epidemiology at the Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Spix C; German Childhood Cancer Registry (GCCR) Division of Childhood Cancer Epidemiology at the Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Pokaż więcej
Źródło:
Cancer causes & control : CCC [Cancer Causes Control] 2024 Jan; Vol. 35 (1), pp. 33-41. Date of Electronic Publication: 2023 Aug 02.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/drug therapy
Neoplasms*/epidemiology
Neoplasms*/radiotherapy
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Child ; Humans ; Adolescent ; Case-Control Studies
Czasopismo naukowe
Tytuł:
Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study.
Autorzy:
Kjaer TK; Cancer Survivorship, Danish Cancer Institute, Copenhagen, Denmark. Electronic address: .
Andersen EAW; Statistics and Data Analysis, Danish Cancer Institute, Copenhagen, Denmark.
Ursin G; Cancer Registry of Norway, Oslo, Norway; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
Larsen SB; Cancer Survivorship, Danish Cancer Institute, Copenhagen, Denmark; Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Bidstrup PE; Cancer Survivorship, Danish Cancer Institute, Copenhagen, Denmark; Institute of Psychology, University of Copenhagen, Copenhagen, Denmark.
Winther JF; Childhood Cancer Research Group, Danish Cancer Institute, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Borre M; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
Johansen C; Center for Cancer Late Effect Research CASTLE, Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Dalton SO; Cancer Survivorship, Danish Cancer Institute, Copenhagen, Denmark; Danish Research Center for Equality in Cancer, Department of Clinical Oncology & Palliative Care, Zealand University Hospital, Næstved, Denmark; Institute of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło:
The Lancet. Oncology [Lancet Oncol] 2024 Jan; Vol. 25 (1), pp. 126-136. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms, Second Primary*/epidemiology
Neoplasms, Second Primary*/etiology
Cancer Survivors*
Neoplasms*/epidemiology
Neoplasms*/complications
Adult ; Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Incidence ; Risk Factors ; Hormones ; Denmark/epidemiology ; Registries
Czasopismo naukowe
Tytuł:
Incidence, risk and prognosis of second primary malignancy of patients with gastric adenocarcinoma.
Autorzy:
Jin L; Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.; Department of Oncology, The Wujin Clinical College of Xuzhou Medical University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.
Su X; Department of Public Course, Jiangsu College of Nursing, Science Road No. 9, Huai'an, 210023, Jiangsu, China.
Li W; Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.; Department of Oncology, The Wujin Clinical College of Xuzhou Medical University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.
Wu J; Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.; Department of Oncology, The Wujin Clinical College of Xuzhou Medical University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.
Zhang H; Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China. .; Department of Oncology, The Wujin Clinical College of Xuzhou Medical University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 08; Vol. 14 (1), pp. 5766. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms, Second Primary*/pathology
Adenocarcinoma*/epidemiology
Stomach Neoplasms*/epidemiology
Humans ; Incidence ; SEER Program ; Risk Factors ; Prognosis
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies